share_log

基石藥業-B：截至二零二四年十二月三十一日止年度之年度業績公告

CSTONE PHARMA-B: ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED DECEMBER 31, 2024

HKEX ·  Mar 27 08:30

Summary by Moomoo AI

基石藥業公佈，截至2024年12月31日止年度，總收入為4.07億元人民幣，同比下降12.2%。其中授權費收入增長113.1%至2.04億元，特許權使用費收入為2812萬元，藥品銷售收入為1.75億元。年內虧損由上年度的3.67億元大幅收窄75.2%至9121萬元，主要受益於營運開支顯著減少。公司研發開支同比減少74.5%至1.35億元，主要由於里程碑費用及第三方合約成本減少。銷售及市場推廣開支下降32.9%至1.34億元，行政開支減少57.4%至7780萬元。截至2024年底，公司現金及現金等價物和定期存款為6.73億元。在產品開發方面，舒格利單抗已在歐盟和英國獲批用於一線治療IV期非小細胞肺癌，並與多家公司建立區域商業化合作。CS5001在臨床試驗中展現出令人鼓舞的療效，針對非霍奇金淋巴瘤和霍奇金淋巴瘤的客觀緩解率分別達到70%和100%。公司亦啟動了CS2009的全球I期臨床試驗，並持續推進多個早期研發項目。
基石藥業公佈，截至2024年12月31日止年度，總收入為4.07億元人民幣，同比下降12.2%。其中授權費收入增長113.1%至2.04億元，特許權使用費收入為2812萬元，藥品銷售收入為1.75億元。年內虧損由上年度的3.67億元大幅收窄75.2%至9121萬元，主要受益於營運開支顯著減少。公司研發開支同比減少74.5%至1.35億元，主要由於里程碑費用及第三方合約成本減少。銷售及市場推廣開支下降32.9%至1.34億元，行政開支減少57.4%至7780萬元。截至2024年底，公司現金及現金等價物和定期存款為6.73億元。在產品開發方面，舒格利單抗已在歐盟和英國獲批用於一線治療IV期非小細胞肺癌，並與多家公司建立區域商業化合作。CS5001在臨床試驗中展現出令人鼓舞的療效，針對非霍奇金淋巴瘤和霍奇金淋巴瘤的客觀緩解率分別達到70%和100%。公司亦啟動了CS2009的全球I期臨床試驗，並持續推進多個早期研發項目。
Cornerstone Pharmaceutical announced that for the fiscal year ending December 31, 2024, total revenue was 0.407 billion yuan, a year-on-year decrease of 12.2%. Among this, licensing income increased by 113.1% to 0.204 billion yuan, royalty income was 28.12 million yuan, and pharmaceutical sales revenue was 0.175 billion yuan. The loss for the year narrowed significantly by 75.2% from the previous year's 0.367 billion yuan to 91.21 million yuan, mainly benefiting from a significant reduction in operating expenses.The company's research and development expenses decreased year-on-year by 74.5% to 0.135 billion yuan, primarily due to reduced milestone payments and third-party contract costs. Sales and marketing expenses fell by 32.9% to 0.134 billion yuan, while administrative expenses dropped by 57.4% to 77.8 million yuan. As of the end of 2024, the company had...Show More
Cornerstone Pharmaceutical announced that for the fiscal year ending December 31, 2024, total revenue was 0.407 billion yuan, a year-on-year decrease of 12.2%. Among this, licensing income increased by 113.1% to 0.204 billion yuan, royalty income was 28.12 million yuan, and pharmaceutical sales revenue was 0.175 billion yuan. The loss for the year narrowed significantly by 75.2% from the previous year's 0.367 billion yuan to 91.21 million yuan, mainly benefiting from a significant reduction in operating expenses.The company's research and development expenses decreased year-on-year by 74.5% to 0.135 billion yuan, primarily due to reduced milestone payments and third-party contract costs. Sales and marketing expenses fell by 32.9% to 0.134 billion yuan, while administrative expenses dropped by 57.4% to 77.8 million yuan. As of the end of 2024, the company had cash and cash equivalents and fixed deposits totaling 0.673 billion yuan.In terms of product development, Sugilizumab has been approved for first-line treatment of stage IV non-small cell lung cancer in the European Union and United Kingdom, and regional commercialization collaborations have been established with several companies. CS5001 has shown encouraging efficacy in clinical trials, achieving objective response rates of 70% and 100% for non-Hodgkin lymphoma and Hodgkin lymphoma, respectively. The company has also initiated global phase I clinical trials for CS2009 and continues to advance multiple early-stage research projects.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 339

Recommended

Market Insights

Warren Buffett Portfolio Warren Buffett Portfolio

Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.

No. Symbol 5D % Chg
Sample Name
Sample Code
 +13.15%
Sample Name
Sample Code
 +11.03%
Sample Name
Sample Code
 +9.98%
4
Jefferies Financial
JEF
+9.78%
5
Nu Holdings
NU
+9.23%
Unlock Now

Discussing

2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current Show More
Will you choose to follow in Buffett's investment?
84%
16%
Follow
Wait and see
725 votes
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs
President Donald Trump’s tariffs on more than 180 countries and territories are causing havoc across the global market, with the $S&P 500 Index (.SPX.US)$ has fallen 18.71% from its recent highs, nearing bear market territory. Meanwhile, the tech-heavy $NASDAQ 100 Index (.NDX.US)$ has dropped 23% from its all-time high.
In fact, Jeff Bezos, Larry Ellison, and Mark Zuckerberg each lost close to $10 billion by...

Discussing

FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
Fed rate cut expectations for 2025 intensify. What’s your market outlook?
44%
56%
Bullish
Bearlish
1595 votes
FOMC Press Conference, March 19, 2025

- No more -

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
OK